REIMBURSEMENT CLINIC: Killing two birds with one stone
This article was originally published in Clinica
In Clinica’s new reimbursement Q&A series, Dr Mark Charny of UK consultancy Translucency discusses how careful strategizing can help companies fulfil evidential needs for both regulatory approval and reimbursement while avoiding costly mistakes
You may also be interested in...
In the final part of Clinica’s series on heath technology assessment in the EU, Mark Charny looks beyond HTA and discusses what factors to consider when gauging the reimbursement potential of your product from a payer’s perspective
In the second part of Clinica’s new series on health technology assessment in the EU, Mark Charny discusses how medtech companies can plan their HTA strategy on a country-specific level and on a broader EU level
Mark Charny provides an update on the key initiatives that have been rolled out in the EU to support cross-border collaboration on health technology assessment for medical devices.